Wednesday, May 30, 2012


o    ORIGIN results (Lantus CV outcome trial)
o    US and Northern European Epidemiological Study (Lantus and cancer data)
o    Sanofi: results from EASIE trial (Lantus vs Januvia)
o    Eli Lilly: Humalog-PEG long-acting insulin (10 abstracts including phase 2 results in T1DM and T2DM)
o    Halozymes: results from phase 2 (rapid-acting insulin analogues+hyaluronidase vs Humalog in T1DM and T2DM)

·         Insulin-GLP-1 loose combinations:
o    Lyxumia: GetGoal-Duo trial (lixisenatide vs placebo as add-on to Lantus+met±TZD)
o    Lyxumia: GetGoal-L trial (lixisenatide vs placebo as add-on to basal insulin ±met)
o    Lyxumia: GetGoal-P trial (lixisenatide vs placebo as add-on to TZD±met)

·         GLP-1:
o    Albiglutide: Harmony 6 trial (albiglutide vs Humalog as add-on to Lantus)
o    Albiglutide: Harmony 7 trial (albiglutide vs Victoza© as add-on to OADs)
o    Bydureon: 4-year data
o    Bydureon: 2-year data (add-on to TZD)

·         OADs:
o    Dapagliflozin (SGLT2 inhibitor): results from T2DM patients with cardiovascular disease ±hypertension
o    Dapagliflozin (SGLT2 inhibitor): add-on to DPP-4±met
o    Dapagliflozin (SGLT2 inhibitor): Two-year results in T2DM
o    Canagliflozin (SGLT2 inhibitor): results from subjects inadequately controlled with diet & exercise or met+SU

Source : Novo Nordisk

No comments:

Post a Comment